Weekly roundup: Next-gen science, next-level investment
ViCentra raises $85M to scale manufacturing and accelerate market penetration of Kaleido insulin patch pump
ViCentra announces the successful close of an upsized $85 million Series D financing led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations. With this fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry.
Novo Holdings co-leads Phasecraft’s $34 million Series B financing to bring quantum computing closer to solving real-world challenges
Novo Holdings announces it has co-led the $34 million Series B financing of Phasecraft, the world’s leading quantum algorithms company. The funds will be used to accelerate Phasecraft’s breakthrough work to transform quantum computing’s theoretical promise into practical applications.
Advanced Medical Solutions Group plc – Notice of interim results
Advanced Medical Solutions Group, a world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2025 on Wednesday, 17 September 2025.
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
Resolution Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy to treat inflammatory and fibrotic diseases, announced that the first patient has been dosed and safety cleared in its Phase I/II EMERALD study. The patient received the therapy at the Royal Infirmary of Edinburgh, a leading NHS hospital. EMERALD is evaluating RTX001, a first-in-class engineered RMT for patients with a history of decompensated liver cirrhosis. The study, which is taking place in the UK and Spain, is now open for full enrolment.
Resolution is hosting an R&D Webinar on Wednesday 17th September 2025 at 2pm BST / 9am ET / 6am PT alongside world leading clinical hepatologists Professor Jonathan Fallowfield, Dr. Elliot Tapper. Please use the following link to register.
Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors
Blue Cell Therapeutics, a biotech developing “off-the-shelf” allogeneic stem cell therapies for diseases where angiogenesis and nerve regeneration are beneficial, including severe erectile dysfunction following prostate surgery, announces the appointment of Olav Hellebø as Chairman of its Board of Directors.
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), announces that it will be presenting new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, at the 22nd International Myeloma Society (IMS) Annual Meeting, being held in Toronto, Canada, on 17 to 20 September 2025.
📺Optimum TV
With little over a month until Optimum’s 17th Annual Healthcare Investor Conference – to be held on Thursday October 9th at The King’s Fund in London – this week we kicked off our Countdown to Conference series on Optimum TV by talking to Philip Brainin, Associate at Sound Bioventures. Philip is chairing the panel ‘Next-gen VCs, next-gen biotech: the future is (already) here’.
Philip discusses why junior VCs are vital to the industry, why he picked venture capital over being a doctor or pursuing academic research, and how we can better measure the true value of innovative medicines. Watch the full episode here ⬇️
🔥Hot topic
There’s great excitement about new disease-modifying treatments for Alzheimer’s disease – plus a raft of experimental drugs in development for Alzheimer’s and other forms of dementia. But with the number of dementia cases globally predicted to triple by 2050, this week’s Hot Topic asks, “Is the world prepared?” ⬇️
👥Industry events
Optimum’s 17th Annual Healthcare Conference
We are thrilled to announce that our agenda for Optimum’s 17th Annual Healthcare Investor Conference is complete and what a stellar line up of speakers we have!
📅 Join us on 9th October at The King’s Fund, London, to hear from those that are shaping the markets and discover how to refine your narrative to attract the right investment – this is where science meets strategy.
See the full agenda and register your interest in attending today.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
